Editor’s Note Archive

IPR, public health, policy reform at tipping point in India

Read more

Converting India Biotech Inc’s potential into reality

Read more

Gleevec, Nexavar cases put India’’s IP laws to test

Read more

Testing the barometer for biosimilars

Read more

A Lakshman Rekha in pharma FDI

Read more

New guidelines for biosimilars in India

Read more

Obamacare passed, but will Obama?

Read more

Putting a price to health

Read more

Good growth, but will it continue?

Read more

Agreeing to disagree

Read more